Insider Trading June 29, 2026 07:54 PM

Adaptive Biotechnologies Director Sells $1.05M in Stock Under Pre-Arranged Plan

Michelle Griffin's transaction follows strong Q1 earnings and a proposed corporate split, as the biotech firm prepares to issue $250 million in convertible notes.

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
ADPT

Adaptive Biotechnologies Corp (NASDAQ:ADPT) Director Michelle Renee Griffin executed a sale of 52,084 common shares on June 25, 2026, valued at approximately $1,051,055. The transactions occurred under a Rule 10b5-1 trading plan established in November 2025, with shares sold at a weighted-average price of $20.18, reflecting a range between $20.00 and $20.55. This sale followed the full exercise of 52,084 vested stock options, which were converted at an exercise price of $7.80 per share, equating to an acquisition value of $406,255. Post-transaction, Griffin retains direct ownership of 15,625 shares. The sale occurs as ADPT trades near its 52-week high of $21.64, following an 81.5% price increase over the past year. The company, valued at $3.41 billion, is currently viewed as overvalued based on InvestingPro analysis. Recent developments include Adaptive Biotechnologies reporting Q1 2026 revenue of $70.9 million, surpassing the $60.89 million forecast, primarily driven by growth in its Minimal Residual Disease (MRD) business. The firm also announced plans to separate its MRD and Immune Medicine units, targeting a resolution by the end of 2026. Additionally, Adaptive Biotechnologies plans to issue $250 million in convertible senior notes due 2031 via private placement, with an upsized option for an additional $37.5 million. These notes will be senior, unsecured obligations with semi-annual interest payments. BTIG reaffirmed a Buy rating and a $22.00 price target, citing the business separation and notes offering as key factors in its positive outlook.

Adaptive Biotechnologies Director Sells $1.05M in Stock Under Pre-Arranged Plan
ADPT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Adaptive Biotechnologies Director Michelle Griffin sold $1.05M in stock under a pre-arranged trading plan, following the exercise of vested options.
  • The biotech firm reported Q1 2026 revenue of $70.9M, surpassing forecasts, driven by growth in its Minimal Residual Disease business.
  • Adaptive Biotechnologies plans to separate its MRD and Immune Medicine units and issue $250M in convertible senior notes, prompting a reaffirmed Buy rating from BTIG.

Adaptive Biotechnologies Corp (NASDAQ:ADPT) Director Michelle Renee Griffin sold 52,084 shares of common stock on June 25, 2026, for a total value of approximately $1,051,055. The shares were sold at a weighted-average price of $20.18, with individual transactions ranging from $20.00 to $20.55. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which Ms. Griffin adopted on November 7, 2025. The timing of the sale comes as the stock trades near its 52-week high of $21.64, following an 81.5% surge over the past year.

The sale followed the exercise of 52,084 stock options, which were fully vested and exercisable. These options were converted into common stock at an exercise price of $7.80 per share, representing an acquisition value of $406,255. Following these transactions, Ms. Griffin directly holds 15,625 shares of Adaptive Biotechnologies Corp common stock.

The company, valued at $3.41 billion, currently appears overvalued according to InvestingPro analysis. For investors seeking deeper insights, InvestingPro offers 15 additional ProTips for ADPT, plus comprehensive Pro Research Reports covering 1,400+ US stocks with expert analysis and actionable intelligence.

In other recent news, Adaptive Biotechnologies Corporation reported impressive financial results for the first quarter of 2026, with revenue reaching $70.9 million, significantly exceeding the forecast of $60.89 million. This strong performance was largely driven by the growth of its Minimal Residual Disease (MRD) business. Additionally, the company announced plans to separate its MRD and Immune Medicine units, aiming to identify a preferred separation path by the end of 2026. In a related development, Adaptive Biotechnologies plans to offer $250 million in convertible senior notes due 2031 in a private placement, with an option for initial purchasers to buy an additional $37.5 million in notes. The notes will be senior, unsecured obligations with interest payable semi-annually. BTIG reiterated a Buy rating and a $22.00 price target for the company, following the announcement of these business updates. The decision to separate its businesses and the upsized convertible notes offering were key factors in BTIG’s continued positive outlook.

Risks

  • The company's valuation is currently viewed as overvalued, suggesting potential downside risk for investors.
  • The planned separation of business units introduces execution uncertainty, with a target resolution date of late 2026.
  • The issuance of $250M in convertible notes may dilute existing shareholders and increase leverage, impacting the balance sheet.

More from Insider Trading

Tempus AI CFO James Rogers Executes $634,095 Stock Sale Under Pre-Arranged Plan Jun 29, 2026 Tempus AI Director Jennifer Doudna Executes Pre-Arranged Stock Sale Amidst Corporate Developments Jun 29, 2026 Alphabet Executive Marsida Saraci Offloads $153k in Class C Stock Amid Broader Corporate Developments Jun 29, 2026 Glenbrook Capital Management Expands SenesTech Position Amid Market Contraction Jun 29, 2026 Metropolitan Bank Executive Navigates Pre-Arranged Sales Amid Strong Financial Performance Jun 29, 2026